tyratech is in the business of bringing to market safe and ... · tyratech naturals® mosquito...

2 © 2013 TyraTech, Inc. Confidential Information of TyraTech, Inc.

TyraTech is in the business of bringing to market safe and efficacious solutions to control insects and

parasites both internal and external

0

100

Pesticides Natural Tyratech

% Safety

% Efficacy


Providing solutions to real problems

Problem Tyratech’s Solution

Head Lice

Treatment

- Synthetic chemicals do not

work (resistance)

- Silicon based products have

poor aesthetics (oily residues)

- Safe

- No resistance (100% kill)

- Fast acting (15 mins)

- Excellent aesthetics (non-oily)

Insect repellent

- DEET accounts for 70% of

current solutions - Safety issues

- Side effects

- Other solutions less efficacious

- More efficacious than DEET

15%

- Safe (not DEET)

Animal Health

- Current product is pesticides - Lower efficacy

- Unsafe for animals (premises

cleared during application)

- May contaminate water supply

- Unsafe for food chain

- Non-pesticide

- Kills 100%

- Safe for animals, environment,

food chain and water supply


TyraTech in commercialisation phase

Manufacturing

Clinical data

Registration

EU - USA Commercialisation

Head Lice

VaMousse

- Major chain in USA (8,500

pharmacies)

- Additional 8,000 stores in USA

- Advanced discussions in UK

Insect repellent

Tyratech’s

Naturals

- Advanced discussions with

15,000 stores in USA

- Advanced discussions in UK

Biocides

Novartis AH - Worldwide distribution

- Market leader


Global Partnerships

$16m

NOVARTIS

$210bn

AMVAC

$0.8bn

Target

$40bn

Mondelez

$60bn

Home Depot

$110bn


Animal Health


Significant for TyraTech Endorsement of TYR technology

Access to worldwide market (up to $1b)

Quick to market

Strong partnership with market leader

Main elements of the partnership Distribution agreement

Novartis Brand, marketing and technical support

More than 6 products + pipeline

Worldwide

TyraTech – Novartis AH Partnership


VaMOUSSE The BIGGEST innovation in Head Lice control

*Number one issue with consumers

-100% efficacy on lice and nits including

resistant strains*

-Kills fast in one application (15 minutes)

- Superior cosmetics (non-oily mousse

- Convenient and precise application

-Non toxic (no chemical pesticides)

-No restriction on reuse


Full Range of Products

Mousse Prevent Repel

TREATMENT PREVENT/REPEL

Single treatment

Infestation

Daily Shampoo

Prevention

Daily repellent

Prevention

Mosquito

and Tick

Repellent


Greater Repellency vs. 15% DEET

Greater Repellency vs. Leading Naturals

Repels mosquitoes for up to 8 hours

Repels ticks for up to 4 hours

Non-DEET formula

Non-toxic, no synthetic pesticides

Safe for use on the whole family

Can be reapplied

Tyratech Naturals® Mosquito & Tick

Repellent

An Innovation in Personal Repellent


Superiority versus 15% DEET validated in EPA

Reference Lab

• “The evident superiority of Tyratech in a challenging laboratory study is remarkable

• Tyratech repelled about 30-50% longer than the DEET 15% product tested

• Works more consistently for a wider variety of individual consumers than DEET 15%”

Dr. Scott P. Carroll, Ph.D

Carroll-Loye Biological Research.

UC Davis - US EPA Reference Laboratory

6.45

4.7

0

2

4

6

8

10 TyraTech Naturals (5% Geraniol)

15% Deet

“TyraTech Naturals

repelled 30-50%

longer than the 15%

deet product tested”

Mosquito Repellence

Hours

Market Segment Opportunities

• Lighter fragrance

• Up to 4 hours efficacy

• Extra strength

• Up to 8 hours efficacy

Backyard Outdoors


Full Range of Products

Family Camp Repellent

Wipes

Repellent

Sunscreen Pocket Aerosol


TyraTech growth potential Strong Pipeline

Fly repellent (cattle, horses)

“Mist formulation”

6 core products

Control in environment

Prevention Shampoo

and repellent

Mousse and lotion

Diffuser, clip-on

Sunscreen repellent

Wipes

Outdoor / backyard

Spray repellent

Animal Health Repellent Head Lice

Companion animals,

poultry, aquaculture


TyraTech growth potential New technology platforms

New

Platforms

New repellents

Antimicrobial

Antifungal

Endo

parasites Plastics

Long lasting

formulation


TyraTech growth potential Geographical expansion

Step 1: USA - UK Step 2: EU Step 3: RoW


Summary & Outlook

Breakthrough products providing solutions to unmet global problems

$6-8bn addressable market

Strong partnerships in place with major global players

In commercialisation phase

High growth potential Extensive product pipeline Geographic expansion

Poised for significant revenue generation .

Appendix

Technology

Commercialisation Phase

Key Market Segments

Animal Health

VaMousse

Tyratech Naturals

Management Team

Shareholders and Capital Structure

Disclaimer


TyraTech’s breakthrough technology targets G-protein coupled receptors

Target of 50% of all modern medicinal drugs*

TyraTech targets the tyramine receptor in insects and parasites

Specific to invertebrates and

inactive in humans, providing a superior level of safety

Proprietary platform allows TYR to identify highly effective blends

*Filmore D (2004). "It's a GPCR world". Modern Drug Discovery (American Chemical Society) 2004 (November): 24–28.


TyraTech is at the commercialisation phase of developing its platforms

Platform Pipeline Products Profits

2008 – 2012 2012 – beyond

DEVELOPMENT PHASE Platform development Patented blends and formulations Clinical studies

COMMERCIALISATION PHASE Products registered Commercialisation partners Geographical and channels expansion


TyraTech will focus initially on two major segments for a total addressable market of $6bn – $8bn*

Personal Care

Market size $1bn – $2bn*

Head Lice Repellent Functional Food

Animal health

Market size $5bn – $6bn*

Production animal facilities

Repellent External parasites Internal parasites


Insects in animal facilities cause economic losses

Flies cause billions of dollars of losses to the worldwide meat and dairy industry (biting, pathogen transmission, and nuisance swarming)

Cockroaches are mechanical vectors of viruses, bacteria, and endoparasites. They threaten biosecurity by easily moving among barns

Current pesticides have important limitations

Often unable to treat barns when animals are present

Zero tolerance for pesticide residue in milk (problem for dairy cattle)

Overuse led to increased insect resistance

High restrictions due to risk of contaminating aquatic systems

Health risks to pesticide applicators due to repeated exposure

ANIMAL HEALTH - Insects in livestock facilities cause economic losses - current pesticides have important limitations


TyraTech offers a range of products for use in Integrated Pest Management (IPM) practices

ANIMAL HEALTH - The TyraTech Solution

Product highlights: Contact killers provide rapid knockdown

and kill

Safe for use around animals

Safe for use in aquatic systems

Safe for use around food preparation areas

No risk of contamination of meat, milk, and the environment


Comparison to Hedrin

VaMousse Hedrin Once Hedrin Mousse

Kills 100% lice, nits Reduced performance after

shampoo 2 applications

Non oily formulation

Action in 15 min

Kills in 2-3 hours Leave 8 hours


OTC Market Competition (RID®, NIX®)

Resistance developed to these pesticide-based products According to the NEJM “60 percent of (head lice) are now resistant to one or more

common treatments.

Toxicity of pesticide-based treatments “Treatment of head lice infestation relies on the application of topical

insecticides”. Journal of the American Academy of Dermatology

Natural products not viable alternative to synthetics

Limited proven clinical efficacy

No clear market leader

Limited product promotion

Current products not meeting customers needs

Source: Journal of the American Academy of

Dermatology Volume 67, Issue 6 , Pages 1143-1150,

December 2012

http://www.jaad.org/issues?issue_key=S0190-9622(11)X0027-0


100% efficacy against lice

4.6%

100%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Mortality Results at Two Weeks - Single 10 min Application

% N

it M

ort

alit

y

Head Lice Nit Mortality (10 July 2013, Dip Bioassay, 3 reps - 100-150 nits/rep)

UTC TT Head Lice Killer

100% efficacy against nits (eggs)

Superior efficacy verified in

Independent Clinical Setting

Nix, Rid are lead competitors

(permethrin-based)

0

20

40

60

80

100

Average % mortality at 4 h post-treatment

Water

Rid®

Nix®

TyraTechNaturals

* Test conducted at LiceSource Services, Inc.,

Plantation, FL, USA * Test conducted by I. Burgess, Cambridge Labs, UK


Current products do not meet consumer needs Mosquitoes /ticks are major threat

~$200 Million market Driven by increasing mosquito infestation Increased concern about vector driven disease

Current products (80% based on DEET molecule)

Safety concerns, especially for children Strong odor, dissolves plastics (fishing, hunting, golf, etc.) Newly documented resistance issues Low efficacy against ticks

Current natural products don’t provide the repellency consumers want

Limited repellency against mosquitos and ticks Unpleasant odor


Field Tested and Peer Reviewed Repellency

Peer-Reviewed Journal Articles:

Mosquito Trials: Journal of Medical Entomology •

• Performance of the plant-based repellent TT-4302 against mosquitoes in the laboratory and field and comparative efficacy to 16 mosquito repellents against Aedes aegypti (Diptera: Culicidae).

Tick Trials: Experimental and Applied Acarology

• Activity of the plant-based repellent, TT-4302 against the ticks Amblyomma americanum, Dermacentor variabilis, Ixodes scapularis and Rhipicephalus sanguineus (Acari: Ixodidae)

• Exp Appl Acarol DOI 10.1007/s10493-013-9719-1


Laboratory Trials: Results Aedes aegypti

Longer mosquito repellency than DEET (15%) and Natural repellents


Experienced Management Team

Alan Reade (Executive Chairman) was appointed on May 25, 2007 as Non-executive Director and as Executive Chairman in January 2010 From 2000 until his retirement in 2005, he served as Executive Chairman of Merial Limited, a

leading animal health company and joint venture between Merck & Co. Inc. and Sanofi- Aventis

Chief Executive Officer of Rhone-Poulenc Agro Inc. and member of the Global Management Board

Bruno Jactel (CEO and Director) was appointed on January 1, 2013. Chief Marketing Officer of Merial, the $2.6bn revenue generating animal health division of

Sanofi. Prior to this, Dr. Jactel was Vice-President of European operations at Merial During this time, Merial built the most successful consumer brand in animal health history

with FRONTLINE (Flea and tick product for pets) reaching $1bn in annual revenue in 2009 He earned his degree as a Doctor in Veterinary Medicine at Toulouse University (France) and

his Masters in Economics at the Sorbonne University in Paris


Capital Structure Total Shares Outstanding 168.8 m • Restricted Shares TYR 141.5 • Unrestricted Shares TYRU 27.3

Market Cap (@ 6p) £ 10 million Top 7 Shareholders c. 70% Debt nil

Shareholders and capital structure

29%

12%

9% 7%

6%

5%

4%

28%

Shareholders % Holding

American VanguardGroup

Legal & General

Sustainable AssetManagement

Close AssetManagement

A. Reade

HendersonGlobalInvestors

Fiske

Other

American Vanguard Group is a strong TYR strategic partner


This presentation has been prepared by TyraTech, Inc. (the “Company”).

The information in this presentation is being given to you solely for your preliminary information on a confidential basis and neither it nor its contents may be reproduced, redistributed or passed on or

disclosed, in whole or in part, to any other person. In particular, neither this presentation nor any copy thereof may be taken, transmitted, distributed or sent, directly or indirectly, in or into Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada or to any resident thereof or in or into the United States or to any US Person (as defined in Regulation S promulgated under the United States Securities Act of 1933 (as amended) (the “Securities Act”)). The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdiction.

Within the United Kingdom this document is directed at and may only be communicated to persons who are both (a) “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (“Qualified Investors”) or other persons to whom it may lawfully be distributed without giving rise to the requirement for a prospectus under the Prospectus Directive; and (b) either (i) persons who have professional experience in matters relating investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (“FSMA”) (Financial Promotion) Order 2005 (the “Order”); (ii) high net worth entities falling within Article 49 of the Order; or (iii) other persons to whom it may lawfully be communicated, (all such persons together known as “Relevant Persons”).

The content of this document has not been approved for distribution in the United Kingdom by an authorised person. Such approval is required by section 21 of FSMA unless an appropriate exemption

applies. Reliance on this document for the purpose of engaging in any investment activity may expose a significant risk of losing all the property invested or of incurring additional liability. If you are in any doubt about the investment to which this document relates you should consult an independent financial adviser or other authorised person under the FSA who specialises in advising on the acquisition or disposal of shares and other securities.

Any investment or investment activity to which this document relates is available in the United Kingdom only to Relevant Persons. Any person who is not a Relevant Person should not act or rely on this

presentation or any of its contents and any investment or investment activity to which it relates will only be available to Relevant Persons. Any person who is unsure of their position should seek independent advice.

This document does not constitute a prospectus, and does not constitute, or form part of, any offer to sell or issue, or any solicitation of subscriptions for the Company’s securities, nor should it be relied on in connection with any such sale, issue or subscription.

No Shares have been offered or sold, or will be offered or sold, to the public in any member state of the European Economic Area to anyone other than qualified investors as defined in the Prospectus Directive.

This document may be distributed in Switzerland to qualified Swiss investors only without the use of advertisements.

The information contained in this presentation is subject to updating, completion, verification and amendment and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company, its shareholders or any of their respective affiliates, advisers (including Nplus1 Singer Capital Markets Limited) or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The forward-looking information contained herein has been prepared on the basis of a number of assumptions which may prove to be incorrect, and accordingly, actual results may vary. In any event, the value of investments can go up as well as down and past performance is not a guide to future returns.

The securities have not been and will not be registered under the Securities Act or under the securities laws of any state of the United States or under the applicable securities laws of Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada. Accordingly, subject to certain exceptions, such securities may not, directly or indirectly, be offered, sold, transferred, taken up or delivered in or into the United States of America, Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada or to or for the account or benefit of any national, resident or citizen of such countries or to any US Person as defined in Regulation S under the Securities Act. No action has been taken or will be taken by the Company or its shareholders or by Nplus1 Singer Capital Markets Limited that would permit a public offer of shares in the Company or possession or distribution of this presentation where action for that purpose is required.

The Shares have not been recommended by any United States federal or state securities commission or regulatory authority. The foregoing authorities have not confirmed the accuracy of or determined

the adequacy of this document. Any representation to the contrary is a criminal offence in the United States. This document has been prepared pursuant to rules and requirements other than those promulgated under the United States federal securities laws and may not contain disclosures customary, expected or required in securities registration transactions prepared pursuant to the US rules and requirements.

Disclaimer

tyratech is in the business of bringing to market safe and ... · tyratech naturals® mosquito...

Documents